Drug–Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors

Annals of Pharmacotherapy - Tập 43 Số 7-8 - Trang 1266-1274 - 2009
Nicholas B. Norgard1, Kathryn D. Mathews2, Geoffrey C. Wall3
1School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY
2Cardiology Clinical Pharmacist, Intermountain Medical Center; Adjunct Professor, College of Pharmacy, University of Utah; Adjunct Professor, College of Pharmacy, University of Southern Nevada
3Internal Medicine Clinical Pharmacist, Iowa Methodist Medical Center, Associate Professor of Pharmacy Practice, College of Pharmacy and Health Sciences, Drake University

Tóm tắt

Objective:To evaluate the interaction between clopidogrel and proton pump inhibitors (PPIs).Data Sources:Literature retrieval was accessed through PubMed (1980–January 2009), abstracts from 2008 American Heart Association and 2009 Society of Cardiovascular Angiography and Interventions Scientific Sessions, and media press releases using the terms clopidogrel, proton pump inhibitors, cytochrome 2C19, genetic cytochrome P450 polymorphisms, and drug interaction. In addition, reference citations from publications identified in the search were reviewed.Study Selection and Data Extraction:Relevant original research articles and review articles were evaluated. Articles were selected if they were published in English and focused on any of the key words or appeared to have substantial content addressing the drug interaction.Data Synthesis:Recent attention has been placed on a potential interaction observed between clopidogrel and the widely used PPIs. Preliminary evidence suggests that omeprazole interacts with clopidogrel, reducing clopidogrel's antiplatelet effects as measured by various laboratory tests. Most data indicate that the interaction involves the competitive inhibition of the CYP2C19 isoenzyme. The interaction appears to be clinically significant, as several retrospective analyses have shown an increase in adverse cardiovascular outcomes when PPIs and clopidogrel are used concomitantly. However, this may not be a class effect.Conclusions:Available data suggest that omeprazole is the PPI most likely to have a significant interaction with clopidogrel. Further studies are needed to determine that an interaction between the other PPIs and clopidogrel does not exist. In situations in which both clopidogrel and a PPI are indicated, pantoprazole should be used since it is the PPI least likely to interact with clopidogrel.

Từ khóa


Tài liệu tham khảo

10.1002/ccd.10497

10.1161/01.CIR.0000130846.46168.03

10.1016/j.jacc.2005.07.041

10.1016/j.jacc.2005.07.056

Lev E, 2006, Am Heart J, 153, 41

10.1016/j.jacc.2006.06.065

10.1016/j.jacc.2006.10.050

10.1160/TH06-07-0362

10.1111/j.1538-7836.2007.02609.x

10.1016/j.jacc.2008.07.068

10.1016/j.jacc.2007.07.090

10.1016/j.jacc.2008.08.002

10.1016/j.jacc.2007.02.013

Drug Topics. Top 200 generic and brand drugs by units in 2007. http://drugtopics.modernmedicine.com/drugtopics/article/articleList.jsp?categoryId=7604 (accessed 2009 Jan 10).

10.1055/s-0038-1648859

Kurihara A, 2005, Drug Metab Rev, 37, 99

10.2133/dmpk.23.412

10.1038/sj.clpt.6100139

10.1182/blood-2006-04-013052

10.1016/j.jacc.2007.12.056

10.1111/j.1538-7836.2008.03050.x

10.1056/NEJMoa0809171

10.1007/s00210-001-0489-7

10.1016/j.clpt.2006.07.007

10.1002/bmc.1128

Caplain H, 1999, Semin Thromb Hemost, 25, 25

10.1097/FTD.0b013e31815c13fd

10.1055/s-0037-1614133

10.1111/j.1538-7836.2004.01063.x

10.1111/j.1538-7836.2006.02162.x

10.1016/j.jacc.2007.06.064

10.1016/j.jacc.2008.05.053

10.1161/circ.118.suppl_18.S_815

Medco MediaRoom. New study: a common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. http://medco.mediaroom.com/index.php?s=43&item=352 (accessed May 2009).

10.1161/circ.118.suppl_18.S_1165

10.1161/circ.118.suppl_18.S_815-a

10.1503/cmaj.082001

10.1001/jama.2009.261

Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm (accessed January 2009).

Society of Cardiovascular Angiography and Interventions. SCAI Statement on “A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study.” www.sci.org/drlt1.aspx?PAGE_ID=5870 (accessed May 2009).

10.2165/00003088-200847010-00001

Abelo A, 2000, Drug Metab Dispos, 28, 966, 10.1016/S0090-9556(24)15171-9

10.1124/dmd.32.8.821

10.2165/00003088-199120010-00003

10.2165/00002018-200629090-00002

10.1007/s00228-004-0841-1

10.1016/S0149-2918(00)83025-8

10.1038/clpt.1992.172

10.1046/j.1365-2036.2001.00980.x

10.1016/j.ahj.2008.09.017

10.1177/0091270008315310

10.1046/j.0306-5251.2001.01499.x

10.2165/00003088-200241120-00002

10.1016/j.clpt.2005.10.002

10.7326/0003-4819-129-12-199812150-00006

10.1111/j.1572-0241.2006.00717.x

10.1056/NEJMoa0808227

10.1097/00042737-200105000-00025

10.1111/j.1365-2036.2004.02161.x

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 43 Số 7-8

1266-1274

Thông tin tác giả